New, Potent, and Selective Peptidic Oxytocin Receptor Agonists
journal contributionposted on 26.06.2014 by Kazimierz Wiśniewski, Sudarkodi Alagarsamy, Robert Galyean, Hiroe Tariga, Dorain Thompson, Brian Ly, Halina Wiśniewska, Steve Qi, Glenn Croston, Regent Laporte, Pierre J.-M. Rivière, Claudio D. Schteingart
Any type of content formally published in an academic journal, usually following a peer-review process.
Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex. Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation. The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V2 receptor mediated antidiuresis. We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly7]dOT), 47 (carba-6-[Phe2,BuGly7]dOT), 55 (carba-6-[3-MeBzlGly7]dOT), and 57 (carba-1-[4-FBzlGly7]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60–80 mL min–1 kg–1. Compound 57 (FE 202767) is currently in clinical development for the treatment of preterm mothers requiring lactation support.